摘要
目的检测人肝细胞癌(HCC)中突变型P53和Ki67的表达,并探讨其与临床病理特征的关系及其在预后评估中的意义。方法采用免疫组织化学SP法检测病理确诊的102例HCC中突变型P53和Ki67的表达,分析两者与HCC临床病理特征的关系。结果 HCC中突变型P53和Ki67表达率分别为50.98%(52/102)和48.04%(49/102);突变型P53和Ki67的表达分别在有无肿瘤脉管浸润组间、有无淋巴结转移组间、TNMⅠ+Ⅱ期与Ⅲ+Ⅳ期组间比较差异有统计学意义(P<0.05、P<0.01或P<0.001),在患者性别、年龄、肿瘤大小、Edmondson分级、有无肝硬化、HBsAg阳性/阴性组间分别比较突变型P53和Ki67的表达率,结果差异均无统计学意义(P>0.05);突变型P53和Ki67的阳性表达呈正相关(r=0.472,P<0.001)。结论检测突变型P53和Ki67的表达可能对HCC的发展和预后判断具有临床价值。
Objective To detect the expressions of mutant P53 and Ki67 in human hepatocellular carcinoma (HCC), and to explore their relationships with clinicopathological parameters of HCC. Methods An im- munohistochemical staining SP method was used to detect the expressions of mutant P53 and Ki67 in 102 cases of human hepatocellular carcinoma proven by pathological examination. The correlation of expressions of mutant P53 and Ki67 in hepatocellular carcinoma with clinicopathological features were analyzed. Results The positive expression rates of mutant P53 and Ki67 in tissues of hepatocellular carcinoma were 50.98% (52/102) and 48.04% (49/102), respectively. Comparing the mutant P53 and Ki67 expressions in patients with tumor vascular invasion and without vascular invasion, and in patients with lymph node metastasis and without lymph node metastasis, and in patients with TNM stages Ⅰ+Ⅱ and with stages Ⅲ+Ⅳ, results yielded statistical differences ( P〈0.05, P 〈0.01 or P〈0. 001), respectively. Comparing the mutant P53 and Ki67 expression rates in patients of sex groups, of age groups, of tumor size groups, of Edmondson grading groups, of groups with or without cirrhosis, and of positive- and negative-groups showed no statistical significant differences ( P〉0.05). Mutant P53 was positively correlated with positive expression of Ki67 ( r = 0. 472, P〈0. 001). Conclusion Detection of mutant P53 and Ki67 has clinical value in predicting the development and prognosis of human hepatocellular carcinoma.
出处
《右江民族医学院学报》
2017年第3期172-175,共4页
Journal of Youjiang Medical University for Nationalities